Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF ...

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care. Neoadjuvant (primary ...

The US Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb) in combination with ipilimumab (Yervoy, Bristol-Myers Squibb) for the treatment of patients with ...

Neoadjuvant targeted and immunotherapy in stage 3 melanoma showed significant pathologic responses, especially in BRAF-mutated cases, with 66.7% achieving major pathologic response. The trial ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...